KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $6.02 $13.63 Friday, 26th Apr 2024 VERV stock ended at $6.16. This is 0.96% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.47% from a day low at $6.02 to a day high of $6.41.
90 days $6.02 $19.34
52 weeks $6.02 $21.42

Historical Verve Therapeutics, Inc. prices

Date Open High Low Close Volume
Mar 21, 2024 $13.61 $14.26 $13.05 $13.21 857 321
Mar 20, 2024 $12.95 $13.54 $12.67 $13.38 755 301
Mar 19, 2024 $13.10 $13.48 $12.89 $13.01 858 050
Mar 18, 2024 $13.84 $13.84 $12.82 $13.31 835 021
Mar 15, 2024 $13.54 $14.03 $13.47 $13.81 3 728 372
Mar 14, 2024 $14.18 $14.18 $13.39 $13.60 958 057
Mar 13, 2024 $13.85 $14.51 $13.85 $14.34 949 651
Mar 12, 2024 $14.57 $14.57 $13.60 $13.92 1 068 532
Mar 11, 2024 $14.99 $15.55 $14.23 $14.42 877 138
Mar 08, 2024 $15.37 $16.03 $14.73 $14.96 636 079
Mar 07, 2024 $15.21 $15.81 $14.91 $14.94 936 900
Mar 06, 2024 $15.42 $15.62 $14.92 $15.07 1 184 729
Mar 05, 2024 $15.66 $16.05 $14.84 $15.14 1 102 533
Mar 04, 2024 $16.40 $16.43 $15.37 $15.84 1 312 349
Mar 01, 2024 $17.07 $17.33 $16.15 $16.29 1 792 620
Feb 29, 2024 $18.96 $19.34 $16.89 $17.05 1 880 640
Feb 28, 2024 $16.57 $18.95 $16.56 $17.96 2 149 919
Feb 27, 2024 $15.29 $17.73 $15.00 $17.54 2 393 804
Feb 26, 2024 $13.28 $14.53 $13.23 $14.44 1 033 727
Feb 23, 2024 $13.25 $13.56 $13.20 $13.45 546 344
Feb 22, 2024 $13.30 $13.77 $13.12 $13.32 787 076
Feb 21, 2024 $12.90 $13.21 $12.65 $13.13 525 169
Feb 20, 2024 $12.87 $13.47 $12.87 $13.06 696 077
Feb 16, 2024 $12.89 $13.32 $12.64 $13.09 675 642
Feb 15, 2024 $12.81 $13.54 $12.81 $13.28 920 330
Click to get the best stock tips daily for free!

About Verve Therapeutics, Inc.

Verve Therapeutics. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with... VERV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT